BR112017009989A2 - método para tratar, prevenir, ou reduzir o risco de infecção de pele - Google Patents

método para tratar, prevenir, ou reduzir o risco de infecção de pele

Info

Publication number
BR112017009989A2
BR112017009989A2 BR112017009989-6A BR112017009989A BR112017009989A2 BR 112017009989 A2 BR112017009989 A2 BR 112017009989A2 BR 112017009989 A BR112017009989 A BR 112017009989A BR 112017009989 A2 BR112017009989 A2 BR 112017009989A2
Authority
BR
Brazil
Prior art keywords
treat
risk
prevent
reduce
skin infection
Prior art date
Application number
BR112017009989-6A
Other languages
English (en)
Portuguese (pt)
Inventor
M. Duffy Erin
Original Assignee
Melinta Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Melinta Therapeutics, Inc. filed Critical Melinta Therapeutics, Inc.
Publication of BR112017009989A2 publication Critical patent/BR112017009989A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Cosmetics (AREA)
BR112017009989-6A 2014-11-14 2015-11-16 método para tratar, prevenir, ou reduzir o risco de infecção de pele BR112017009989A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462080212P 2014-11-14 2014-11-14
US62/080,212 2014-11-14
PCT/US2015/060851 WO2016077818A1 (en) 2014-11-14 2015-11-16 Method for treating, preventing, or reducing the risk of skin infection

Publications (1)

Publication Number Publication Date
BR112017009989A2 true BR112017009989A2 (pt) 2018-01-02

Family

ID=55955188

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017009989-6A BR112017009989A2 (pt) 2014-11-14 2015-11-16 método para tratar, prevenir, ou reduzir o risco de infecção de pele

Country Status (21)

Country Link
US (1) US10471046B2 (https=)
EP (1) EP3217974A4 (https=)
JP (1) JP2017534654A (https=)
KR (1) KR20170084200A (https=)
CN (1) CN107205989A (https=)
AR (1) AR102666A1 (https=)
AU (1) AU2015346023A1 (https=)
BR (1) BR112017009989A2 (https=)
CA (1) CA2967825A1 (https=)
CL (1) CL2017001245A1 (https=)
CR (1) CR20170196A (https=)
EA (1) EA201791051A1 (https=)
HK (1) HK1244211A1 (https=)
IL (1) IL252197A0 (https=)
MX (1) MX389005B (https=)
NI (1) NI201700057A (https=)
PH (1) PH12017500887A1 (https=)
SG (1) SG11201703856VA (https=)
SV (1) SV2017005444A (https=)
UY (1) UY36402A (https=)
WO (1) WO2016077818A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180011843A (ko) 2015-06-11 2018-02-02 바실리어 파마슈티카 인터내셔널 리미티드 유출-펌프 억제제 및 이의 치료적 용도
AU2017371353B2 (en) * 2016-12-09 2022-02-03 Celltaxis, Llc Monamine and monoamine derivatives as inhibitors of leukotriene A4 hydrolase
CN107721943A (zh) * 2017-10-26 2018-02-23 沈阳药科大学 含联芳基腙结构的噁唑烷酮类化合物及其制备方法
KR20190130243A (ko) 2018-05-14 2019-11-22 (주)텔리언 트러스트 인덱스를 이용한 공유경제 시스템 및 방법
PL3992177T3 (pl) 2019-06-25 2024-08-26 Amtixbio Co., Ltd. Nowatorska pochodna kwasu aminoalkanowego, zawierająca w swojej strukturze ugrupowanie bifenylowe, oraz kompozycja farmaceutyczna o działaniu przeciwgrzybiczym, w skład której wchodzi ta pochodna
CN115677679A (zh) * 2021-07-26 2023-02-03 沈阳药科大学 含联芳基腙结构的噁唑烷酮化合物及其制备方法和应用
CN120794967A (zh) * 2024-04-10 2025-10-17 沈阳药科大学 联芳基噁唑烷酮类化合物及其应用

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES332272A1 (es) 1965-10-20 1967-11-16 Milwaukee Chaplet & Mfg Company Inc Un dispositivo regulador de programa.
GB1185685A (en) 1966-01-11 1970-03-25 Quinoderm Ltd Method of Making Pharmaceutical Compositions
US3418055A (en) 1967-04-03 1968-12-24 Schwartzman Gilbert Pressure operated applicator and cap construction
US3410645A (en) 1967-05-08 1968-11-12 Schwartzman Gilbert Concave diaphragm applicator
US3535422A (en) 1968-03-11 1970-10-20 Stiefel Laboratories Stable benzoyl peroxide composition
US3669323A (en) 1969-12-12 1972-06-13 American Can Co One-way valve insert for collapsible dispensing containers
US4056611A (en) 1973-04-16 1977-11-01 Stiefel Laboratories, Inc. Therapeutic composition
GB1541463A (en) 1975-10-11 1979-02-28 Lion Dentifrice Co Ltd Process for prparing a multiple emulsion having a dispersing form of water-phase/oil-phase/water-phase
US4620648A (en) 1982-07-06 1986-11-04 Dab-O-Matic Corp. Pressure-responsive valve
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4985459A (en) 1984-02-08 1991-01-15 Richardson-Vicks, Inc. Analgesic and anti-inflammatory compositions comprising diphenhydramine and methods of using same
US4693623A (en) 1984-03-02 1987-09-15 Dab-O-Matic Corp. Pressure-responsive valve for an applicator
US4999186A (en) 1986-06-27 1991-03-12 The Procter & Gamble Company Novel sunscreen agents, sunscreen compositions and methods for preventing sunburn
US4937370A (en) 1987-06-02 1990-06-26 The Procter & Gamble Company Novel chromophores, sunscreen compositions and methods for preventing sunburn
US4960764A (en) 1987-03-06 1990-10-02 Richardson-Vicks Inc. Oil-in-water-in-silicone emulsion compositions
US4800197A (en) 1987-07-17 1989-01-24 Richardson-Vicks Inc. Anti-acne composition
US4891228A (en) 1988-02-02 1990-01-02 Richardson-Vicks Inc. Medicated cleansing pads
US4891227A (en) 1988-02-02 1990-01-02 Richardson-Vicks Inc. Medicated cleansing pads
US4919934A (en) 1989-03-02 1990-04-24 Richardson-Vicks Inc. Cosmetic sticks
US5087445A (en) 1989-09-08 1992-02-11 Richardson-Vicks, Inc. Photoprotection compositions having reduced dermal irritation
US5073371A (en) 1990-11-30 1991-12-17 Richardson-Vicks, Inc. Leave-on facial emulsion compositions
US5073372A (en) 1990-11-30 1991-12-17 Richardson-Vicks, Inc. Leave-on facial emulsion compositions
ATE146783T1 (de) 1991-11-01 1997-01-15 Upjohn Co Substituierte aryl- und heteroaryl- phenyloxazolidinone
US5688792A (en) 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
WO1996030377A1 (en) 1995-03-27 1996-10-03 Isis Pharmaceuticals, Inc. Nitrogenous macrocyclic compounds
ES2169811T3 (es) 1995-09-22 2002-07-16 Wakunaga Pharma Co Ltd Nuevos derivados del acido piridonacarboxilico o sus sales y agente antibacteriano que comprende el mismo como ingrediente activo.
US5763263A (en) 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
US6413981B1 (en) 1999-08-12 2002-07-02 Ortho-Mcneil Pharamceutical, Inc. Bicyclic heterocyclic substituted phenyl oxazolidinone antibacterials, and related compositions and methods
BR0111280A (pt) 2000-06-05 2003-06-10 Dong A Pharm Co Ltd Novos derivados de oxazolidinona e um processo para a preparação dos mesmos
US20130059774A1 (en) * 2000-08-01 2013-03-07 Mahesh Vithalbhai Patel Efflux pump inhibitors
US20030096850A1 (en) * 2001-10-11 2003-05-22 Ford Charles W. Treating infections by administration of oxazolidinones
AR043050A1 (es) 2002-09-26 2005-07-13 Rib X Pharmaceuticals Inc Compuestos heterociclicos bifuncionales y metodos para preparar y usar los mismos
CN1780846A (zh) 2003-03-05 2006-05-31 Rib－X医药品有限公司 双官能杂环化合物及其制备和使用方法
CN101429170B (zh) 2003-06-03 2015-05-13 梅林塔医疗有限公司 联芳基杂环化合物的制备和用途
JP5043428B2 (ja) * 2003-06-03 2012-10-10 リブ−エックス ファーマシューティカルズ，インコーポレイテッド ビアリール複素環式化合物ならびにその製造および使用方法
EP1660465B1 (en) 2003-07-29 2014-12-17 Melinta Therapeutics, Inc. Process for the synthesis of biaryl oxazolidinones
WO2005012270A2 (en) 2003-07-29 2005-02-10 Rib-X Pharmaceuticals, Inc. Biaryl heterocyclic amines, amides, and sulfur-containing compounds and methods of making and using the same
AR046782A1 (es) 2003-12-17 2005-12-21 Rib X Pharmaceuticals Inc Compuestos heterociclicos de biarilo halogenados, composiciones farmaceuticas que los contienen, metodos para su elaboracion y su uso como medicamentos.
JP2008508271A (ja) 2004-07-28 2008-03-21 リブ−エックス ファーマシューティカルズ，インコーポレイテッド ビアリール複素環式化合物ならびにその化合物を製造および使用する方法
EP2816033A1 (en) 2004-07-30 2014-12-24 Abbvie Inc. Preparation of pyridonecarboxylic acid antibacterials
US7728143B2 (en) 2004-10-08 2010-06-01 Abbott Laboratories Salt and crystalline forms thereof of a drug
WO2006110815A1 (en) 2005-04-11 2006-10-19 Abbott Laboratories Pharmaceutical compositions having improved dissolution profiles for poorly soluble drugs
DE602006019870D1 (de) 2005-06-08 2011-03-10 Rib X Pharmaceuticals Inc Verfahren zur synthese von triazolen
EP3290427A1 (en) 2005-08-24 2018-03-07 Melinta Therapeutics, Inc. Triazole compounds and methods of making and using the same
JP2009506063A (ja) 2005-08-24 2009-02-12 リブ−エックス ファーマシューティカルズ，インコーポレイテッド トリアゾール化合物ならびにこれを作製する方法および使用する方法
WO2011139832A2 (en) * 2010-04-28 2011-11-10 Rib-X Pharmaceuticals, Inc. Method for treating mycobacterial infections

Also Published As

Publication number Publication date
EP3217974A4 (en) 2018-07-25
EA201791051A1 (ru) 2018-01-31
CN107205989A (zh) 2017-09-26
US20160136137A1 (en) 2016-05-19
EP3217974A1 (en) 2017-09-20
CL2017001245A1 (es) 2018-02-09
SG11201703856VA (en) 2017-06-29
UY36402A (es) 2016-06-30
US10471046B2 (en) 2019-11-12
WO2016077818A1 (en) 2016-05-19
SV2017005444A (es) 2017-08-31
KR20170084200A (ko) 2017-07-19
AU2015346023A1 (en) 2017-06-01
JP2017534654A (ja) 2017-11-24
NI201700057A (es) 2017-09-04
IL252197A0 (en) 2017-07-31
PH12017500887A1 (en) 2017-11-06
CA2967825A1 (en) 2016-05-19
HK1244211A1 (zh) 2018-08-03
AR102666A1 (es) 2017-03-15
CR20170196A (es) 2017-07-10
MX2017006319A (es) 2017-08-10
MX389005B (es) 2025-03-20

Similar Documents

Publication Publication Date Title
BR112017009989A2 (pt) método para tratar, prevenir, ou reduzir o risco de infecção de pele
BR112018005318A2 (pt) ?polipeptídeos de lisina ativos contra bactérias gram-negativas?
MX394895B (es) Composiciones útiles para el tratamiento de infecciones por staphylococcus aureus.
BR112017000398A2 (pt) composto ou sal do mesmo, método de tratamento de uma infecção causada por dirofilaria immitis, e, kit.
AR101740A1 (es) Terapia de combinación y composiciones
NI201600051A (es) Combinaciones de inhibidores de histona desacetilasa y farmacos inmunomoduladores
PH12017501646A1 (en) Antimicrobial compounds and methods of making and using the same
CR20160308A (es) Combinaciones de inhibidores de histona deacetilasa y farmacos inmunomoduladores
BR112017000520A2 (pt) composto ou sal do mesmo, uso um composto ou de um sal, e, kit.
MX2015016319A (es) Terapia de combinacion que comprende oxazolidinona-quinolonas para uso en el tratamiento de infecciones bacterianas.
BR112017004153A2 (pt) métodos para tratamento de infecções por protozoários
BR112016012599A2 (pt) composição, e, método para tratamento ou prevenção de uma infecção por staphylococcus aureus
BR112019005040A2 (pt) aplicação de pridopidina para tratamento de síndrome de rett
DK3432900T3 (da) Mælkesyrebakteriesammensæting til behandling af bakterielle vaginale infektioner forårsaget af gardnerella vaginalis og, hvis de forefindes, samtidige svampeinfektioner
MX2017004318A (es) Composiciones y metodos para el tratamiento y profilaxis de infecciones del sitio quirurgico.
BR112019004791A2 (pt) tratamento de esclerose múltipla com chs-131
MX2015012455A (es) Metodo para el tratamiento de la enfermedad de higado graso.
EA201692493A1 (ru) Противомикробные фармацевтические композиции со способностями ингибирования множественной лекарственной устойчивости
BR112018002763A2 (pt) método para cicatrização de ferimentos
BR112016014099A2 (pt) método de tratamento de feridas
BR112017002449A2 (pt) tratamento de sintomas associados com terapia de privação androgênica
MX2016012623A (es) Combinacion de adapaleno y peroxido de benzoilo para tratar cicatrices de acne.
AR103636A1 (es) Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol
ECSP16095557A (es) Métodos para tratar infecciones
CR20160591A (es) Metodos para tratar infecciones

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: MELINTA SUBSIDIARY CORP. (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements